Clinical Trial Update: Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SHR1459 tablets in patients with primary membranous nephropathy evaluating efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• SHR1459

Snippet

Sponsor: Reistone Biopharma Company Limited | Conditions: Primary Membranous Nephropathy | Phase 2 | Status: UNKNOWN